Radiopharmaceutical supplierMallinckrodt Medical is taking the jump into technetium-basedcardiac scintigraphy. The St. Louis-based company said last weekthat it has filed a new drug application (NDA) with the Food andDrug Administration for TechneScan
Radiopharmaceutical supplierMallinckrodt Medical is taking the jump into technetium-basedcardiac scintigraphy. The St. Louis-based company said last weekthat it has filed a new drug application (NDA) with the Food andDrug Administration for TechneScan Q12, a technetium-99m agentfor myocardial perfusion imaging.
Mallinckrodt claims that TechneScan Q12 clears more rapidlyfrom the liver than other agents, reducing the level of hepaticuptake that can interfere with cardiac imaging. This may allownuclear medicine physicians to conduct cardiac imaging proceduresmore quickly by reducing the time between injection and imaging,according to the company.
Clinical studies with TechneScan Q12 also indicate that theagent is retained in the myocardium for extended periods of time,prolonging the availability of clear images.
Mallinckrodt's entry into the market for technetium-based cardiacradiopharmaceuticals will increase the number of competitors challengingDu Pont Merck, which has experienced strong market acceptancefor its Cardiolite agent since the product's introduction in 1991(SCAN 1/16/91). Another company vying for Cardiolite's marketshare is Amersham/Medi-Physics, which is waiting for FDA clearancefor Myoview, also a technetium-based agent.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.